Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Tremeau Pharmaceuticals

Tremeau Pharmaceuticals
2016 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Seed LATEST DEAL TYPE
$5.2M LATEST DEAL AMOUNT
Description

Provider of non-opioid pain treatments for rare diseases and other unique patient conditions with no approved treatments. Tremeau's approach to acute and chronic pain in rare diseases is rooted in the mechanism of action, documented efficacy, and clinically differentiated profile of COX-2 selective NSAIDs.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • One Broadway
  • 14th Floor
  • Cambridge, MA 02142
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Tremeau Pharmaceuticals’s full profile, request a free trial.

Tremeau Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 14-Feb-2018 $5.2M 00.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Tremeau Pharmaceuticals Executive Team (3)

Name Title Board
Seat
Contact
Info
Bradford Sippy Co-Founder, Chief Executive Officer & Chairman
Mark Corrigan MD Co-Founder & President, Research & Development
Stu Mueller Consulting Head of Regulatory and Quality Assurance

Tremeau Pharmaceuticals Board Members (1)

Name Representing Role Since Contact
Info
Bradford Sippy Tremeau Pharmaceuticals Co-Founder, Chief Executive Officer & Chairman 000 0000